Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 9Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Glioblastoma 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Glioma 3Fallopian Tube Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Astrocytoma 3Skin Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Neoplasms, Plasma Cell 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

Filgrastim 5Ifosfamide 3Docetaxel 3Carboplatin 3belinostat 2Sunitinib 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Gemcitabine 2Etoposide 2Epirubicin 2Doxorubicin 2toripalimab 1temsirolimus 1tanespimycin 1resiquimod 1poly ICLC 1perifosine 1pegfilgrastim 1pazopanib 1liposomal doxorubicin 1ivosidenib 1etoposide phosphate 1enasidenib 1apatinib 1angiotensin I (1-7) 1alanosine 1Vincristine 1Topotecan 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Chondrosarcoma × poly ICLC × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡